PET/CT with [68Ga]-[18F]-PSMA agents have emerged as a highly sensitive and specific modality for the initial staging of PCa, mainly in patients at high and very high risk for the disease [11,13]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.